BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

It is a truth universally acknowledged, to borrow from Jane Austen, that a single-payer system will say “no” to new technology. If they accept it at all, they do so only when the prices are...
BC Extra | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BioCentury | Sep 7, 2015
Strategy

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BC Week In Review | Feb 23, 2015
Company News

AstraZeneca pl pharmaceuticals news

AstraZeneca agreed to pay the U.S. government $7.9 million to settle allegations that it engaged in a kickback scheme with Medco Health Solutions Inc. in violation of the False Claims Act. Express Scripts Holding Co....
BioCentury | Sep 2, 2013
Strategy

Back to School: Facing Reality

BC Staff  For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices...
BC Week In Review | Jul 15, 2013
Company News

Vivus endocrine/metabolic news

Vivus investor First Manhattan Co. said Anthony Zook agreed to serve as the biotech's CEO if First Manhattan's slate of proposed directors are elected to the Vivus board at the company's upcoming July 15 annual...
BC Week In Review | May 27, 2013
Clinical News

Gattex regulatory update

NPS Pharmaceuticals Inc. (NASDAQ:NPSP), Bedminster, N.J.   Product: Gattex ( Revestive - EU) teduglutide ( ALX-0600 )   Business: Gastrointestinal   NPS disclosed in its 1Q13 earnings that reimbursement of prescriptions for Gattex teduglutide to treat short bowel syndrome...
BC Week In Review | May 20, 2013
Company News

Vivus, Express Scripts sales and marketing update

Vivus said obesity drug Qsymia phentermine/topiramate was added to the national formulary for Express Scripts' Medco Health Solutions Inc. subsidiary, with a co-pay of about $50-$60 for a monthly prescription. In addition, the Veterans Administration...
BC Week In Review | Apr 15, 2013
Company News

Medco, University of Ferrara deal

MRE will collaborate with the university's department of pharmaceutical chemistry to discover adenosine-based compounds for certain adenosine-receptor subtype disorders. MRE will fund the university's research while contracting with an independent laboratory to conduct pharmacological activity...
BC Week In Review | Jan 7, 2013
Company News

Valeant Pharmaceuticals management update

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec   Business: Neurology, Dermatology   Hired: Laizer Kornwasser as group chairman and an EVP, effective Feb. 1, formerly SVP of consumer solutions and retail markets at Medco...
Items per page:
1 - 10 of 170
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

It is a truth universally acknowledged, to borrow from Jane Austen, that a single-payer system will say “no” to new technology. If they accept it at all, they do so only when the prices are...
BC Extra | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BioCentury | Sep 7, 2015
Strategy

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BC Week In Review | Feb 23, 2015
Company News

AstraZeneca pl pharmaceuticals news

AstraZeneca agreed to pay the U.S. government $7.9 million to settle allegations that it engaged in a kickback scheme with Medco Health Solutions Inc. in violation of the False Claims Act. Express Scripts Holding Co....
BioCentury | Sep 2, 2013
Strategy

Back to School: Facing Reality

BC Staff  For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices...
BC Week In Review | Jul 15, 2013
Company News

Vivus endocrine/metabolic news

Vivus investor First Manhattan Co. said Anthony Zook agreed to serve as the biotech's CEO if First Manhattan's slate of proposed directors are elected to the Vivus board at the company's upcoming July 15 annual...
BC Week In Review | May 27, 2013
Clinical News

Gattex regulatory update

NPS Pharmaceuticals Inc. (NASDAQ:NPSP), Bedminster, N.J.   Product: Gattex ( Revestive - EU) teduglutide ( ALX-0600 )   Business: Gastrointestinal   NPS disclosed in its 1Q13 earnings that reimbursement of prescriptions for Gattex teduglutide to treat short bowel syndrome...
BC Week In Review | May 20, 2013
Company News

Vivus, Express Scripts sales and marketing update

Vivus said obesity drug Qsymia phentermine/topiramate was added to the national formulary for Express Scripts' Medco Health Solutions Inc. subsidiary, with a co-pay of about $50-$60 for a monthly prescription. In addition, the Veterans Administration...
BC Week In Review | Apr 15, 2013
Company News

Medco, University of Ferrara deal

MRE will collaborate with the university's department of pharmaceutical chemistry to discover adenosine-based compounds for certain adenosine-receptor subtype disorders. MRE will fund the university's research while contracting with an independent laboratory to conduct pharmacological activity...
BC Week In Review | Jan 7, 2013
Company News

Valeant Pharmaceuticals management update

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec   Business: Neurology, Dermatology   Hired: Laizer Kornwasser as group chairman and an EVP, effective Feb. 1, formerly SVP of consumer solutions and retail markets at Medco...
Items per page:
1 - 10 of 170